Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and...

Area of Science:

• Hematology
• Gene Therapy
• Health Economics

Background:

• Sickle Cell Disease (SCD) poses significant burdens on patients and society.
• Gene therapy offers a promising avenue for treating SCD.
• Lovotibeglogene autotemcel (lovo-cel) is a novel gene therapy for SCD.

Purpose of the Study:

• To evaluate the cost-effectiveness of lovo-cel compared to standard care for SCD patients in the US.
• To assess the long-term clinical and economic outcomes of lovo-cel treatment.
• To analyze the societal and third-party payer perspectives on lovo-cel's value.

Main Methods:

• A patient-level simulation model was developed for lifetime analysis.
• Data from the HGB-206 clinical trial informed lovo-cel efficacy and safety.
• Cost, quality-of-life, and clinical data were sourced from trial data and literature.

Main Results:

• Lovo-cel is predicted to increase life expectancy by 23.8 years and QALYs by 10.2.
• Significant direct and indirect cost savings were observed, including caregiver burden.
• Incremental cost-effectiveness ratios were $191,519 (payer) and $124,051 (societal) per QALY gained.

Conclusions:

• Lovo-cel gene therapy demonstrates meaningful improvements in survival and quality of life for SCD patients.
• The therapy is associated with increased healthcare costs but offers substantial long-term economic value.
• Cost-effectiveness is influenced by long-term clinical effects and societal spillover benefits.